GlassScriptPhysician profile
Mitchell Schwartz
NPI 1962597641
$160,113.64
in general payments reported to CMS, 2019-2025
47 companies · $823 in 2025
The $823 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $16K · 2021: $26K · 2022: $45K · 2023: $45K · 2024: $17K · 2025: $823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $48K · Food and Beverage: $5,219 · Consulting Fee: $4,875 · Travel and Lodging: $4,230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $48,425.00 |
| Food and Beverage | $5,218.98 |
| Consulting Fee | $4,875.00 |
| Travel and Lodging | $4,230.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $131,276.36 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24,262.08 | 2019-2023 | Ofev, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $941.02 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Amgen INC. | $411.24 | 2021-2025 | Tezspire |
| Insmed, INC. | $283.83 | 2019-2025 | Arikayce, Brinsupri |
| Novartis Pharmaceuticals Corporation | $225.87 | 2021-2024 | |
| Jazz Pharmaceuticals INC. | $219.65 | 2019-2025 | Xywav |
| Mylan Specialty L.P. | $184.11 | 2019-2023 | Yupelri |
| Harmony Biosciences LLC | $183.55 | 2023-2025 | Wakix |
| Avadel Cns Pharmaceuticals, LLC | $177.90 | 2023-2025 | Lumryz |
| Grifols USA, LLC | $165.58 | 2022-2024 | Prolastin-C Liquid, Xembify |
| Genentech USA, INC. | $148.15 | 2019-2024 | Xolair |
| Regeneron Healthcare Solutions, INC. | $144.71 | 2020-2023 | Dupixent |
| Verona Pharma, INC. | $120.80 | 2025 | Ohtuvayre |
| United Therapeutics Corporation | $108.30 | 2021-2023 | Tyvaso |
Show all 44 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.